NasdaqGS - Nasdaq Real Time Price USD

Erasca, Inc. (ERAS)

Compare

1.2400

+0.1750

+(16.43%)

At close: 4:00:00 PM EDT

1.2293

-0.01

(-0.86%)

After hours: 5:30:09 PM EDT

Erasca Slides As Insider Purchases Lose Another US$84k

Insiders who bought US$181.9k worth of Erasca, Inc.'s ( NASDAQ:ERAS ) stock at an average buy price of US$2.27 over the...

Simply Wall St. 3 days ago

ERAS
+16.43%
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-d

GlobeNewswire 17 days ago

ERAS
+16.43%
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized data expected in H2 2025 Robust balance sheet with cash, cash equivalents, and marketable securities of $440 million as of December 31, 2024 is expected to fund operations into H2 2027 SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage pre

GlobeNewswire 22 days ago

ERAS
+16.43%
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Tim

GlobeNewswire 2 months ago

ERAS
+16.43%
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)

Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 2 months ago

ERAS
+16.43%
Erasca (NASDAQ:ERAS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 2 months ago

ERAS
+16.43%
Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround

Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 2 months ago

ERAS
+16.43%
Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)

Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 2 months ago

ERAS
+16.43%
Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)

Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 2 months ago

ERAS
+16.43%
Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Management will present on Tuesday, January 14, 2025, at 9:45 am Pacific Time and will also pa

GlobeNewswire 3 months ago

ERAS
+16.43%
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Erasca (ERAS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks 4 months ago

ERAS
+16.43%
Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution across potentially best-in-class RAS targeting franchise; planned IND submissions on track Robust balance sheet with cash, cash equivalents, and marketable securities of $463 million as of September 30, 2024, is expected to fund operations into H1 2027 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Erasca, I

GlobeNewswire 4 months ago

ERAS
+16.43%
Erasca to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings. Guggenheim Securities Healthcare Innovation Conference (November 11 – 13, 2024)Location: InterContinental Ho

GlobeNewswire 5 months ago

ERAS
+16.43%
Erasca Insiders Added US$1.95m Of Stock To Their Holdings

Multiple insiders secured a larger position in Erasca, Inc. ( NASDAQ:ERAS ) shares over the last 12 months. This is...

Simply Wall St. 5 months ago

ERAS
+16.43%
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise

Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib plus trametinib reinforce therapeutic potential in NRASm melanoma and further support ongoing Phase 3 SEACRAFT-2 trial SEACRAFT-2 has potential for approval based on alignment with US and European regulatory agencies on path for tissue-specific indication in melanoma; Stage 1 randomized data expected in 2025 Rapid progress across RAS targeting franchise; planned IND submissions remain on track Erasca to host investor event today at 8:

GlobeNewswire 5 months ago

ERAS
+16.43%
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2 pivotal Phase 3 trial in NRAS-mutant melanoma where favorable survival was previously demonstrated in pooled analyses Erasca to host virtual R&D update for investors on Thursday, October 24, 2024, at 8:30 AM ET SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly f

GlobeNewswire 6 months ago

ERAS
+16.43%
Erasca, Inc. (NASDAQ:ERAS) is favoured by institutional owners who hold 61% of the company

Key Insights Significantly high institutional ownership implies Erasca's stock price is sensitive to their trading...

Simply Wall St. 6 months ago

ERAS
+16.43%
Erasca to Present at Upcoming Investor Conferences in September

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in September 2024 and will also participate in one-on-one investor meetings. 22nd Annual Morgan Stanley Global Healthcare ConferenceLocation: New York Marriott Marquis

GlobeNewswire 7 months ago

ERAS
+16.43%
We're Hopeful That Erasca (NASDAQ:ERAS) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 7 months ago

ERAS
+16.43%
Erasca Reports Second Quarter 2024 Business Updates and Financial Results

In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors Initiated SEACRAFT-2 registrational trial in patients with NRASm melanoma; randomized data for naporafenib plus trametinib vs. trametinib monotherapy expected in 2025 Robust balance sheet with cash, cash equivalents, and marketable securities of $460 million as of June 30, 2024 is expected to fund operat

GlobeNewswire 7 months ago

ERAS
+16.43%

Performance Overview

Return	ERAS	S&P 500 (^GSPC)
YTD	-50.60%	-8.81%
1-Year	-45.85%	+3.16%
3-Year	-84.44%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Erasca, Inc. (ERAS)

Erasca Slides As Insider Purchases Lose Another US$84k

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)

Erasca (NASDAQ:ERAS) Is In A Good Position To Deliver On Growth Plans

Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround

Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)

Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)

Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Erasca to Present at Upcoming Investor Conferences

Erasca Insiders Added US$1.95m Of Stock To Their Holdings

Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise

Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium

Erasca, Inc. (NASDAQ:ERAS) is favoured by institutional owners who hold 61% of the company

Erasca to Present at Upcoming Investor Conferences in September

We're Hopeful That Erasca (NASDAQ:ERAS) Will Use Its Cash Wisely

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

Performance Overview